API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Eisai Inc

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

The CREB-Binding Protein (CBP)/β-Catenin Inhibitor E7386, Co-Created By Eisai and PRISM BioLab, Achieved the Clinical POC (Proof of Concept)

Details:

E7386 is a CBP/β-catenin inhibitor that inhibits CBP and β-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression is expected to suppress tumor.

Lead Product(s): E7386,Lenvatinib

Therapeutic Area: Oncology Product Name: E7386

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: PRISM BioLab

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 01, 2021

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for E7386

E7386